HOME >> MEDICINE >> NEWS
Heart transplant survival: Results may be key to rejection prevention, detection, treatment

Research to be presented at the International Society for Heart and Lung Transplantation (ISHLT) 24th Annual Meeting April 21-24 in San Francisco, points to major victories in the battle for immune system balance in heart transplant patients.

"The combination of emerging technologies and drugs could mean greatly improved patient management and longer survival rates," said Mandeep Mehra, M.D., Program Chair of ISHLT and an ISHLT director. "The results of these studies have been much anticipated by the transplant community."

Some of the late-breaking trial results to be revealed include:

  • Use of intravascular ultrasound as a predictor for long-term heart transplant outcomes Data from a five-year multi-center validation study (Abstract #27)
  • Immunosuppressant drug everolimus used to prevent acute cardiac disease and rejection 24-month study results (Abstract #28)
  • Using molecular testing to predict clinical outcomes for heart transplantation Outcomes of a prospective multi-center trial (Abstract #192)
  • Protection from transplant disease (graft vasculopathy) with use of sirolimus from time of heart transplantation Results from a two-year study (Abstract #193)

Worldwide, approximately 4,500 cardiac transplants are performed annually. Despite significant progress made in surgical techniques and post-operative care, the risks associated with cardiac surgery remain high. The one-year survival rate after transplantation is approximately 80 percent; this number drops to nearly 50 percent after 10 years. The leading cause of death during the first three years is acute rejection of the transplanted organ. The patient's immune system attacks the heart as if it were a foreign object until it no longer functions properly.

Another contributing factor to limited survival rates is cardiac allograft vasculopathy (transplant vessel damage). This thickening of artery walls in a transplanted heart
'"/>

Contact: Kelly Goff
kellygoff@server63.com
210-378-1980
International Society for Heart and Lung Transplantation
19-Apr-2004


Page: 1 2

Related medicine news :

1. The European Society of Cardiology launches Women at Heart
2. Heart surgeons publish death rates
3. Heart attack treatment gap may be closing for women
4. The Larry King Cardiac Foundation presents The Changing Face of Heart Disease on Feb. 2
5. Brenner Childrens Hospital named to NIH Pediatric Heart Network
6. Heart patients treated by non-cardiologists less likely to receive medications
7. Heart failure patients treated for diabetes with insulin have increase in mortality
8. New research results: Heart jacket shown to be effective
9. Heart surgery patients receive less aggressive discharge care
10. Heart attack, stroke risk overlooked in diabetics
11. Heart arrhythmias easily treated, yet few know risks

Post Your Comments:
(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
(Date:7/23/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... with respect to its naloxone-based opioid overdose reversal ... has received an additional commitment from the National ... National Institutes of Health ("NIH"), to fund a ...
(Date:7/23/2014)... CITY, Calif. , July 23, 2014  Cardica, Inc. ... release financial results for its fiscal fourth quarter and year ... the markets close. Cardica,s management will host a conference call ... and provide an update on the company,s business. ... August 7, 2014, at 4:30 p.m. Eastern Time via phone, ...
(Date:7/23/2014)... Colo. , July 23 2014 Ampio ... of its new headquarters, manufacturing and research facility: ... CO 80112 Direct: (720) 437-6500 ... labor efficient, pharmaceutical drug manufacturing facility will be fully ... produce the first batches of Ampion TM necessary ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
Cached News: